Skip to main content
. 2020 Sep 3;11:1297. doi: 10.3389/fphar.2020.01297

Figure 2.

Figure 2

Chemical structures + of different approved and (pre-) clinically developed therapeutic drugs containing Michael acceptors. The Michael acceptor moiety is highlighted in orange. Compounds marked with # are currently studied in clinical trials. CDDO, 2-cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oic acid; DMF, dimethyl fumarate; MA, Michael acceptor; HMC, hesperidin methyl chalcone.